IGC Pharma, Inc.

POTOMAC, Maryland – August 28, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics and AI-enabled tools for Alzheimer’s disease, today announced that Ascendiant Capital Markets has issued an updated equity research report on the Company, raising its 12-month price target to $6.00 per share from $5.50 […]

Ascendiant Capital Markets Raises IGC Pharma Price Target to $6.00, Citing CALMA Progress and Q4 2026 Topline Catalyst  POTOMAC, Maryland – August 28, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics and AI-enabled tools for Alzheimer’s disease, today announced that Ascendiant Capital Markets has issued an updated […]

Regional differences in Alzheimer’s Disease prevalence are often linked with factors such as health infrastructure, socioeconomic status, and lifestyle choices. Addressing these disparities requires a deeper understanding of how culture, social support, and access shape cognitive health.

Phase 2 topline readout expected in Q4 2026 following patient follow-up, database lock, and unblinding

Phase 2 topline readout expected in Q4 2026 following patient follow-up, database lock, and unblinding

IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer’s Trial Approaches Enrollment Closure and Q4 Topline Readout  POTOMAC, Maryland – August 11, 2026 – IGC Pharma,

POTOMAC, Maryland – August 11, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing treatments for Alzheimer’s disease, today announced that it is strengthening its regulatory, biostatistical, artificial intelligence (“AI”)-enabled data science, and strategic pharmaceutical development capabilities as IGC-AD1, the Company’s lead Alzheimer’s drug candidate, advances toward expected […]

IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign POTOMAC, Maryland – July 29, 2026 – IGC Pharma,

POTOMAC, Maryland – July 29, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics for Alzheimer’s disease, today announced that it is evaluating potential civil remedies following the federal jury verdict in United States v. Andrew Left, No. 2:24-CR-456, in the United States District Court for the […]

Seven presentations highlight patent-pending agentic automation, speech-based cognitive models, EHR mining, and predictive analytics designed to support Alzheimer's discovery and clinical development